{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 43,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 30,
  "notes": "Includes two sets of bar charts comparing neutralizing titers across age groups and vaccine doses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/18",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Booster dose could prolong protection and further increase breadth of protection against SARS-CoV-2 variants",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95893890-41fe-47c7-b5a2-129bfe735e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.51,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Neutralizing titers by variant and dose",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "116f540d-2bd8-4d3e-bbb3-13ddadac386e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.51,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Neutralizing titers by age group and dose timing",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fad10603-17b7-4424-a0d1-ce81ac63ad52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "list",
      "text": "3rd dose strongly boosts neutralizing titers both in younger and older adults against Wild type, Delta, and Beta variants. Wild type and Beta variant titers continue to increase. Overall consistent tolerability profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0daa8033-03fe-405b-b4e0-f193516beb89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "Data being prepared for submission to regulatory authorities globally.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "155b0ac5-9364-43e0-857c-8c1b7a8daec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT162b2 Booster Dose Results in a Broad, Robust Neutralisation Response",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb82eb5a-9d7c-4611-bfee-1171e7e2308c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "01b588b4-bf0d-4230-bfc3-b48f811e1dcc",
      "evidence": "The slide contains chart/bar-grouped components showing neutralizing titers by age group and dose timing.",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5f836e48-6c26-4bca-b2f1-fcca570c98e6",
      "evidence": "The slide contains a list/bullet component describing BNT162b2 booster dose results.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "386d1262-e7d2-40f2-862f-00b8814ac33a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document outlines BioNTech's solutions, including its COVID-19 vaccine and pipeline development",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 25,
      "from": 15,
      "beatId": "53c149a8-57e4-41f6-bcc6-f6d3b92e5c06",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents BioNTech's product portfolio, including its COVID-19 vaccine and pipeline candidates",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3bd35679-2871-4f13-9078-94b80c4a49b4",
      "evidence": "The document presents the potential benefits of BioNTech's solutions in addressing various diseases",
      "position": 1,
      "objective": "To highlight the potential consequences of not addressing various diseases with different therapeutic modalities",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}